Table 2 Intervention model parameters. CrI credible interval

Delay between administration and protection (days)

Immediate (fixed)

[16]

 ω_pal

Average period of protection (days)

150 (fixed)

[16]

 e_pal

Efficacy on VHR infants (%)

33.8 (0.0–66.6)¹

[16]

Delay between administration and protection (days)

Immediate (fixed)

[4]

 ω_mab

Average period of protection (days)

275 (fixed)

[4]

 e^S_mab

Efficacy against symptomatic infection (%)

70.1 (52.3–81.0)²

[37]

 e^H_mab

Efficacy against hospitalisation (%)

78.4 (51.9–90.3)³

[37]

 d_vac

Delay between administration and protection (days)

11.4 (2.8–22.1)⁴

[38]

 ω

Average period of protection (days)

Same as post-infection immunity (1/ω)

[38]

 e_vac

Efficacy against all infections (%)

83.0 (75.0–88.0)⁵

[38]

 d²_mat

Average period of protection (days)

133.5 (119.6–146.1)

Same as maternally derived immunity

 e^S_mat

Efficacy against symptomatic infection (%)

41.4 (4.1–64.2)⁶

[5]

 e^H_mat

Efficacy against hospitalisations (%)

53.5 (23.0–71.9)⁷

[5]